Lonza

Summary
About Us
Resources
Contact
Related Service Categories

Lonza

Muenchensteinerstrasse 38

Basel, BS 4052

Switzerland

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com

Company Description

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of more than 19,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Our business is structured to meet our customers’ complex needs across three synergistic Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Our services span from early development to drug substance and drug product manufacturing, and we lead in both established and emerging technologies including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene. Across technologies, we deliver integrated solutions to meet our customers’ needs throughout the entire treatment lifecycle.

Company Background

Founded in 1897 in the Swiss Alps, our business has embraced innovation and kept pace with a fast-changing world for more than 125 years. As the first and the original CDMO, we have been manufacturing medicines for more than four decades. Today we offer one of the largest Western CDMO networks with a global team of 19,000 colleagues working across more than 30 sites in five continents. Our people are united by a common purpose: to turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow.

facilities

We have a global network of over 30 sites. To view our locations, visit: www.lonza.com/about-us/our-locations

Pharmacovigilance in Australia and New Zealand
Drug safety in Australia is regulated via the Office of Medicines Safety Monitoring (OMSM) (synonymous with Adverse Drug Reaction Advisory Committee), a branch of the Therapeutic Goods Administration (TGA). In New Zealand, Medsafe is the regulatory agency responsible for overseeing drug safety/ ...
Drug Supply Modelling in Clinical Trials (Statistical Methodology)
Drug supply chain is very costly and is a well-recognized bottleneck at the design and managing of clinical trials. The innovative risk-based statistical approach to modelling drug supply demand for a single study is proposed. The approach uses the developed technique for predicting the number of ...
Criteria for CMO Selection
Major pharmaceutical and emerging biopharmaceutical companieshave a plethora of choices in utilizing contract-manufacturingorganizations (CMOs) available in the global market place for their custom synthesis needs. However, establishing a collaborative relationship with a few manageable and reliable...
Off-shoring Stability Testing Conducting Cost-efficient Compliant Long-term Stability Studies at Overseas CRO’...
The research-based pharmaceutical industry has always accommodated change, and like other businesses, is increasingly becoming cost constrained due in part to the rising investment required to develop new medicines and the global economic environment.
Biopharmaceutical Contract Manufacturing Market: Outsourcing – What Services are Biomanufacturing Directors ...
As the world economy and financial markets contracted in 2009, so did the market for biopharmaceutical contract manufacturer services.
Outsourcing Compound Inventory Trend or Real Benefits?
A screening compound collection is recognized as a valuable asset by most pharmaceutical companies and Compound Management is now a key component of the Drug Discovery process.